NLRP3 and multiple sclerosis: Fingolimod (FTY-720), a modulator of sphingosine-1-phosphate (S1P) receptor used in the therapy of multiple sclerosis, is known to block NLRP3 inflammasome assembly by downregulating NLRP3, apoptosis-associated speck-like protein (ASC), and caspase-1, thus reducing the levels of TNF-α, IL-6, and IL-1β and promoting microglia polarization into the M2 phenotype (22, 30).